Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares

What Happened Adrian Rawcliffe, a director of Wave Life Sciences (WVE), sold 12,700 shares of company common stock on August 12, 2026. The weighted‑average sale price was $5.29 per share, yielding proceeds of approximately $67,183. The sales were reported on a Form 4 filed August 13, 2026 and are coded as sales (S).

Key Details

• Transaction date: August 12, 2026 (Period of Report)
• Filing date: August 13, 2026 (timely filing; no late filing indicated)
• Shares sold: 12,700 shares
• Price: weighted‑average $5.29; range $5.16–$5.42 per share (multiple transactions)
• Proceeds: ≈ $67,183
• Footnotes: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted March 6, 2026; weighted average price reported and Reporting Person can provide per‑trade price details upon request
• Shares owned after transaction: Not specified in the Form 4 provided
• Exhibit included: Power of Attorney (Exhibit 24.1)

Context This was a sale under a prearranged 10b5‑1 plan, which typically indicates the transactions were executed automatically per a prior plan rather than being ad hoc trades. The filing also notes Wave Life Sciences, Inc. became the successor to Wave Life Sciences Ltd. via a redomiciliation effective August 7, 2026; that change did not alter securityholders' proportional interests. Sales by directors are common and do not by themselves indicate management sentiment.